Shilpa Medicare Limited (SHILPAMED)

864.65

INR
-26.15(-2.94%)
As of December 5, 2024 4:08:00 AM

Shilpa Medicare Limited Share Price Information

24 hour Low and High

Low: 862.3
High: 894.15

All time High

7796.26

Price Change 1h

+₹-26.15 +-2.94%

Price Change 1d

+₹-26.15 +-2.94%

Price Change 1w

+₹-8.60 +-0.98%

Shilpa Medicare Limited Market Information

Exchange

NSE

Market Cap

8261.98 Cr

About Shilpa Medicare Limited Share

Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, recombinant albumin in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. Its APIs also include nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company provides intermediates; high-purity multi-cyclic and long-chain peptides; specialty and biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, orally disintegrating films, transdermal patches, and lyophilized injectables. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

1007

CEO

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • Shilpa Medicare Limited (NSE:SHILPAMED) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
  • What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You
  • Shilpa Medicare shares hit 52-week high on prospects of a huge order; check details
  • Shilpa Medicare Ltd Share Price Today, SHILPAMED Share Price NSE, BSE
  • Investors more bullish on Shilpa Medicare (NSE:SHILPAMED) this week as stock swells 11%, despite earnings trending downwards over past five years

FAQs

Shilpa Medicare Limited (SHILPAMED)

864.65

INR
-26.15(-2.94%)
As of December 5, 2024 4:08:00 AM

Shilpa Medicare Limited Share Price Information

24 hour Low and High

Low: 862.3
High: 894.15

All time High

7796.26

Price Change 1h

+₹-26.15 +-2.94%

Price Change 1d

+₹-26.15 +-2.94%

Price Change 1w

+₹-8.60 +-0.98%

Shilpa Medicare Limited Market Information

Exchange

NSE

Market Cap

8261.98 Cr

About Shilpa Medicare Limited Share

Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, recombinant albumin in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. Its APIs also include nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company provides intermediates; high-purity multi-cyclic and long-chain peptides; specialty and biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, orally disintegrating films, transdermal patches, and lyophilized injectables. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

1007

CEO

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • Shilpa Medicare Limited (NSE:SHILPAMED) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
  • What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You
  • Shilpa Medicare shares hit 52-week high on prospects of a huge order; check details
  • Shilpa Medicare Ltd Share Price Today, SHILPAMED Share Price NSE, BSE
  • Investors more bullish on Shilpa Medicare (NSE:SHILPAMED) this week as stock swells 11%, despite earnings trending downwards over past five years

FAQs